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Resumen 
La literatura en epilepsia y el trastorno bipolar en los inductores está contaminada  por falsos 
negativos. Esta es la segunda parte de una revisión exhaustiva de los fármacos antiepilépticos (FAE) con 
propiedades inductoras que aporta más material educativo  a los clínicos acerca de la complejidad de 
interpretar sus interacciones medicamentosas.  
Se revisa la farmacología básica de inducción incluyendo los citocromos P450 (CYP), las enzimas 
de glucuronización (UGTs) y la glicoproteina P  (P-gp). Los CYP2B6 y CYP3A4 son muy sensibles a la 
inducción.  El CYP1A2 es moderadamente  sensible. Los CYP2C9 y CYP2C19 son sólo  levemente 
sensibles.  El CYP2D6 no se puede inducir con los fármacos.  La inducción de los enzimas metabólicos, 
los CYPs o las UGTs, y los transportadores, como la P-gp, se debe a un aumento en la síntesis de estas 
proteínas mediado por los receptores nucleares (receptores constitutivo androstano,  de los estrógenos, de 
los glucocorticoides y de preganano X).  Aunque la primer parte de este artículo describe factores de 
corrección para los antiepilépticos inductores, la extrapolación de estos valores desde un paciente 
promedio a un individuo concreto está influenciada por la ruta de administración, la carencia de la enzima 
metabólica debida a razones genéticas, y la presencia de inhibidores, u otros inductores.  También pueden 
ser importantes las interacciones farmacológicas de los FAE a nivel de los mecanismos  
farmacodinámicos. Seis pacientes con una sensibilidad extrema  los inductores antiepilépticos son 
descritos.   
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Abstract 
The literature on inducers in epilepsy and bipolar disorder is seriously contaminated by false 
negative findings. Part II of this comprehensive review on antiepileptic drug (AED) inducers provides 
clinicians with further educational material about the complexity of interpreting AED drug-drug 
interactions.  
The basic pharmacology of induction is reviewed including the cytochrome P450 (CYP) 
isoenzymes, the Uridine Diphosphate Glucuronosyltransferases (UGTs), and P-glycoprotein (P-gp). 
CYP2B6 and CYP3A4 are very sensitive to induction.  CYP1A2 is moderately sensitive while CYP2C9 
and CYP2C19 are only mildly sensitive. CYP2D6 cannot be induced by medications. Induction of UGT 
and P-gp are poorly understood. The induction of metabolic enzymes such as CYPs and UGTs, and 
transporters such as P-gp, implies that the amount of these proteins increases when they are induced; this 
is almost always explained by increasing synthesis mediated by the so-called nuclear receptors 
(constitutive androstane, estrogen, glucocorticoid receptors and pregnane X receptors). Although Part I 
provides correction factors for AEDs, extrapolation from  an average to an individual patient may be 
influenced by administration  route, absence of metabolic enzyme for genetic reasons, and presence of 
inhibitors or other inducers. AED pharmacodynamic DDIs may also be important. Six patients with 
extreme sensitivity to AED inductive effects are described.  
Key words:  anticonvulsants; aryl hydrocarbon receptor; constitutive androstane receptor; estrogen 
receptors; glucocorticoid receptor; pregnane X receptor.  
Footnote: Tables 1 to 4 were included in the first part of this article but they are included here to facilitate 
reading. 
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INTRODUCTION 
 The neuropsychopharmacology literature on drug-drug interactions (DDIs) with drug metabolic 
inducers is seriously contaminated by false negative findings. Inducers’ effects are systematically denied 
or at least undervalued, and the published literature on antiepileptic drugs (AEDs)1 and on bipolar 
disorder2  systematically deemphasizes their clinical relevance. This two-part article provides information 
for clinicians to compensate for this oversight in the literature on AED inducers. Part I introduced the 
subject of potent (Table 1) and mild inducers (Table 2) and provided clinical recommendations on 
correcting for the effect of inducers through dose modifications of the induced substrates by using 
correction factors (Table 3).1 As the available literature for calculating these correction factors is seriously 
limited, the author acknowledges that it is likely that in 5 years this review article may be obsolete and 
that the correction factors provided may need to be extensively modified.  
 Unfortunately, it is a major simplification to think that correction factors can completely resolve 
clinicians’ problems when trying to deal with the complex issue of induction in 
neuropsychopharmacology. Many of the drug combinations that neurologists and/or psychiatrists find in 
daily clinical practice are not addressed in Table 3.1  Part I provides a conservative attempt to reflect the 
complexity of the issue by describing mild inducers that can also behave as inhibitors (Table 4). Part II is 
an effort to further educate clinicians about the complex nature of interpreting AED DDIs through the 
provision of basic pharmacological knowledge to help to improve their ability to interpret complex DDIs. 
 Although this second part has much more theoretical information than the first part, the author has 
selected the information according to his experience with the deficiencies of the literature for teaching 
clinicians how to navigate the turbulent waters of DDI with inducers in neuropsychopharmacology. Using 
this practical approach, the author presents seven sections that address three issues: basic pharmacology, 
the true pharmacological complexity of DDI, and the existence of individuals who are unusually sensitive 
to induction. 
1Tables 1 to 4 were developed for part I of this article but are included here to facilitate the lecture. 
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 The basic pharmacology of induction reflects the increased production of the proteins involved in 
pharmacokinetic mechanisms. Inducers increase the metabolism of many neuropsychopharmacological 
drugs metabolized by the Cytochrome P450 (CYP) isoenzymes, the major oxidative enzymes. Inducers 
sometimes increase the activity of other less well understood metabolic enzymes, the Uridine Diphosphate 
Glucuronosyltransferases (UGTs), which are the most important conjugative enzymes. Only very recently 
has it become clear that, besides metabolizing enzymes, another major group of pharmacokinetic proteins 
called transporters, which usually work in tandem with metabolic enzymes to eliminate xenobiotics from 
the body, can also be induced.  P-glycoprotein (P-gp) is the most important transporter and is briefly 
described.  A new rapidly expanding area in the literature, describing nuclear receptors, is beginning to 
provide some understanding of how inducers increase the activity of CYPs, UGTs and P-gp. 
 In summary, basic pharmacology accounts for the first four sections: (1) CYPs, (2) UGTs, (3) P-
gp, and (4) nuclear receptors. The fifth and six sections address the second issue: the complexity of 
interpreting induction in patients on a polypharmacy regimen (which is the norm in patients with epilepsy 
and bipolar disorder). They describe, respectively, that inducer effects need to be understood in the 
context of the complexity of pharmacokinetic polypharmacy and pharmacodynamic DDIs. The seventh 
section does not come from the literature, but from the author’s clinical practice.  It acknowledges that, on 
rare occasions, clinicians find patients who are very sensitive to induction and may require massive dose 
increases of some drugs.  
CYPs 
 CYP terminology can be confusing for clinicians who need to know that CYP names include a 
number for the family, a letter for the subfamily and then another number for the specific isoenzyme. The 
first three CYP families are mainly located in the liver and are involved in the metabolism of xenobiotics 
such as medications.3 They are also important in the activation and deactivation of carcinogens, and they 
may have some not well-understood role in endogenous metabolism.3 The CYP families higher than “3” 
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appear to be mainly involved in the endogenous metabolism of complex molecules including cholesterol 
and its derivate, the steroids.3   
 The first 3 CYP families are part of the oxidative enzymes (traditionally called Phase I metabolic 
enzymes). CYP34A4 is the most important hepatic CYP, accounting for more than one-third of hepatic 
CYPs. Five other hepatic CYPs, CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP2D6, are definitively 
important for the metabolism of neuropsychopharmacological drugs (Table 5), and those prescribers not 
familiar with them need to make a major effort to learn their names and separate one from the other, in 
spite of their confusing names.  
 There are multiple extra-hepatic CYP isoenzymes involved in xenobiotic metabolism not included 
in Table 5, but they are less well understood and less important. The two most important extra-hepatic 
CYPs may be CYP3A4 and CYP3A5.  CYP3A4 is also the most important CYP in the small intestine.4 
The small intestine CYP3A4 (with P-gp; see that section) is a fundamental component of what 
pharmacologists usually call first-pass metabolism. First-pass metabolism5 refers to the substantial 
decrease in absorption of some drugs when using the oral versus the intravenous (IV) route of 
administration.  Metabolism in the intestine and the first time it goes though the liver constitutes first-pass 
metabolism. Although some drugs displaying first-pass metabolism are metabolized by UGTs (e.g., 
asenapine), there is agreement that CYP3A4 (and P-gp) located in the intestine and liver explain first-pass 
metabolism for CYP3A4 substrates. CYP3A5 has high homology with CYP3A4, appears to metabolize 
many of the same substrates as CYP3A4, and is particularly important in kidney drug metabolism. In 
general, for the majority of CYP3A drugs, the contribution of CYP3A5 to their total metabolism is 
thought to be small.6 
 The substrates column in Table 5 describes which drugs in neuropsychopharmacology 7,8 are 
metabolized by the five most important hepatic CYPs. Another column describes the CYP inhibitors.9-13   
Inhibitors usually act by binding to the CYP, making that CYP molecule inactive. The table focuses on 
potent inhibitors that cannot easily be displaced by substrates, but any substrate in the right clinical 
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circumstances can behave as a clinically relevant competitive inhibitor of its drug-metabolizing enzymes.  
Some CYP inhibitors, particularly the female sexual hormones, may not only inactivate some CYPs 
(CYP1A2 and CYP2C19) but may also decrease their synthesis.12 
Table 5’s third column describes the level of induction, which refers to how sensitive the CYP is 
to induction (see the section on complex pharmacokinetic polypharmacy). The next column lists other 
inducers9,14-22 besides AEDs (see Tables 1 and 4). Rifampin is not listed for all five CYPs since it is a 
promiscuous inducer of these five CYPs (and other enzymes). The last column focuses on the complex 
effects of pregnancy, which can increase or decrease the activity of these CYPs.12,23-26    
Genetic variations 
     The first three CYP families include genes that are highly polymorphic, meaning that genetic 
variations affecting their function are frequent. Although it is not well understood, the genetic variations 
of the first CYP families may be related to different evolutionary pressures from environmental 
differences in exposure to different xenobiotics, particularly in the diet.  It is likely that our ancestors, in 
times of hunger, had no choice but to eat whatever plants they could find to palliate their hunger. Many 
plants have toxins on them to protect them from plant-eating animals. As most medications are derived 
from plants, it is not surprising that we use the same CYPs to metabolize medications. Clinicians need to 
know that the first three CYP families vary from species to species; thus, CYP animal studies do not 
extrapolate well to humans and in vitro studies with human hepatocytes are used to study these first three 
CYPs in the laboratory.   
 Clinicians are frequently bombarded by companies marketing the benefits of CYP genotyping. 
The author thinks that to interpret these genotyping results clinicians need a sophisticated knowledge of 
CYP alleles and the technical limitations of the various genotyping techniques. 27-29 
 As summarized in Table 6, the author’s opinion is that most CYP variations are not ready for 
clinical use.29 Only three of them, CYP2C9, CYP2C19 and CYP2D6, may be ready, but CYP2C9 has 
relatively small applications in neuropsychopharmacology. CYP1A2,30,31 CYP2B6,32,33 CYP3A4,34 and 
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CYP3A534,35 genotyping are described as limited since we  have very limited understanding of their 
genetic variations and the genotypic-phenotypic relationships.  It is easy to find articles marketing the 
potential of CYP genotyping by stressing the studies with significant results but ignoring the studies with 
non-significant results and major gaps in understanding the genotype-phenotype relationships. In the other 
extreme, one can find investigators with an evidence-based approach who “undermine” CYP genotyping 
by explaining that it has very little role in selective serotonin reuptake inhibitor (SSRI) prescription. The 
small role of CYP genotyping for many SSRIs dosing has little relevance for the field, since any 
pharmacologist working on SSRIs would have predicted it using pharmacological mechanistic knowledge 
without the need for any systematic review of the literature.36 Regardless, recommendations for dose 
corrections according to CYP2C19 genotyping have been provided for citalopram, escitalopram and 
sertraline.29 
      Therefore, despite the author’s genotyping of more than 5000 patients with CYP2D6 and/or 
CYP2C19,37 he thinks that CYP genotyping should be used judiciously in specific individuals with 
unusual responses that would be compatible with CYP2D6 and/or CYP2C19 genetic abnormalities.  This 
genotyping should be combined with information on inhibitors and inducers. In the author’s experience, 
CYP2D6 and CYP2C19 genotyping can occasionally be useful in patients with peculiar response to some 
psychiatric drugs,38  particularly first-generation psychiatric drugs, since tricyclic antidepressants (TCAs) 
and phenothiazine antipsychotics were mainly metabolized by CYP2D6 and have narrow therapeutic 
windows. As a matter of fact, excellent TCA dosing guidelines based on CYP2D6 and CYP2C19 
genotyping have been developed.7 With second-generation antipsychotics and antidepressants, CYP 
genotyping is less helpful, since they have very different metabolic pathways.9,13,39 Recommendations for 
dose corrections according to CYP2D6 genotyping have been provided for venlafaxine, aripiprazole, 
risperidone, zuclopenthixol and atomoxetine. 29The author is frequently consulted by patients and 
colleagues regarding some extreme subjects who do not tolerate or are not responding to many drugs from 
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the same class, but these situations are not usually explained by CYP genetic variations but by other 
factors.38  
 The most important genetic variations in the first three CYP families are described in Table 2 
27,31,32,37,38,40-54. The terminology of CYP genotyping and phenotyping is pretty confusing for clinicians. Its 
complexity is due to the complex historical development of CYP knowledge.55 First, the concept of poor 
metabolizers (PMs) was described. It was clear that for CYP2D6 and CYP2C19 there were some subjects 
that appeared to have very low metabolic activity. One of the first descriptions referred to TCAs; some 
subjects had very low ability to metabolize TCAs.55 Later, it was discovered that TCAs were metabolized 
by CYP2D6; CYP2D6 PMs are described as those who do not have any CYP2D6 in their livers. Each has 
two inactive CYP2D6 alleles (one inactive allele in one chromosome from the father and another inactive 
allele in the other chromosome from the mother), such that no CYP2D6 protein is produced or, if it is 
produced, it is completely inactive. CYP2D6 phenotypes included PMs, who do not have CYP2D6 in 
their bodies, and normal individuals who were called extensive metabolizers (EMs). The CYP2D6 
population’s phenotype was described as bimodal, one mode for PMs and another for EMs. Later, some 
individuals from one family in Sweden were discovered to have undetectable TCA levels despite taking 
TCAs; they had more CYP2D6 than normal.56 They had from 3 to 13 active CYP2D6 alleles. The patient 
with 3 alleles received 1 normal allele from one parent and 2 active alleles from the other parent (the 
allele had been duplicated). The patient with 13 alleles received 1 normal allele from one parent and 12 
active copies from the other parent (the allele had been multiplied 12 times).  
 CYP2C19 was also discovered to be polymorphic with PMs and EMs55 but has a different racial 
distribution than CYP2D6 (Table 6). Later on, CYP2C19 UMs were also described; they have an allele 
that is associated with higher CYP2C19 expression.  Thus, genetic mechanisms explaining UMs can 
include multiplication of an active gene (this is usually included in the concept of copy number variation) 
such as in CYP2D6, or an allele with increased expression, such as in CYP2C19.  
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 Clinicians need to remember that an individual with an EM genotype can have a PM phenotype 
when he/she is taking a powerful inhibitor that eliminates all the activity of that enzyme.  One can have a 
UM phenotype when he/she is taking a powerful inducer that increases the activity of any relevant 
enzyme.  
 In CYP2C9, no PMs were found but subjects with low activity were found; they were sometimes 
called slow metabolizers. Some subjects, particularly East Asians, were found to have CYP2D6 present 
with low activity. They were called intermediate metabolizers (IMs). Therefore, for CYP2D6 and 
CYP2C19, the genetic variations vary from race to race and include subjects on a continuum from no or 
low activity to those with excessive activity (Table 6).  
 Some very rare subjects, not well studied in the literature, are relevant for prescribers in 
neuropsychopharmacology; they are the “double” PMs for both CYP2D6 and CYP2C19.57  This 
combined genetic variant is very rare (<1/1000) but may be very relevant for antidepressant prescription. 
Most oral antidepressants are metabolized by CYP2D6 and/or CYP2C19; these rare double PMs, in the 
experience of the author, have very negative experience with most antidepressants since they cannot 
tolerate them well in normal doses. However, they should be able to tolerate normal doses of mirtazapine, 
which is not dependent on CYP2D6 or CYP2C19 for its metabolism57 or normal doses of bupropion 
which is mainly metabolized by CYP2B6. 
 Clinicians need to be aware that a new genetic area relevant for CYP function has recently been 
receiving attention, but its clinical relevance is not well established. The CYP oxidoreductase (POR) is a 
microsomal enzyme closely located near the various CYPs; it influences CYP function by donating 
electrons. It has recently been proposed that POR genetic variations may be better predictors of CYP3A4 
phenotype than CYP3A4 genetic variations58 and that POR genetic variants can be associated with 
increased or decreased activity of CYPs from the first three families.59 
UGTs 
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 UGTs are the most important of the conjugation enzymes (traditionally called Phase II metabolic 
enzymes) and are the main metabolic enzymes for a few antipsychotics, a few AEDs, and a few 
benzodiazepines (Table 7). UGTs have been neglected and are less well understood than CYPs.60  
Knowledge of UGTs is 10-15 years behind CYPs, to the point that the information provided in this review 
of UGTs on inducer effects is much less reliable than that of CYP inducers and much more likely to need 
corrections and updates in 5-10 years. Factors contributing to this neglect include: 1) the difficulty of 
developing analytic methods to measure glucuronides; 2) the overlapping activity of UGTs and the lack of 
selective probes; 3) the complexity of the glucuronidation cycle, comprising reabsorption throughout the 
enterohepatic cycle and participation in deconjugation by β-glucuronidases; including those present in 
bacteria; and 4) endogenous compounds that are frequently substrate,  inhibitor or inducer UGTs; this occurs 
more frequently than in CYPs, providing an additional level of complexity in DDIs.61,62  
 UGTs are located in the internal membrane facing the luminal side of the endoplasmic reticulum 
of hepatic and extra-hepatic tissue (particularly skin, lung, small intestine and kidney) with direct access 
to the metabolites resulting from CYPs and oxidizing enzymes.63 More recently, some authors have 
proposed that protein-protein interactions may be important in understanding UGT function. UGTs may 
work by forming complexes of several UGTs which glucuronidate substrates at the same time.62 If that 
idea is proven correct, it would make no sense to try to establish which specific UGT may be important in 
metabolizing a specific substrate. Moreover, there is some limited information that CYPs and UGTs may 
interact to metabolize drugs62 and that UGT function may be crucial in understanding the physiological 
properties of many CYP inhibitors.64 
 UGTs transfer the glucuronyl group from uridine-5' diphosphoglucuronate to many lipophilic 
compounds. The resulting glucuronide is more water-soluble, less toxic, and more easily excreted than the 
parent compound.  Glucuronides account for most of the detoxified material found in bile and urine.  
UGTs have evolved to catalyze the glucuronidation of both endogenous compounds (bilirubin, thyroid 
hormones, sexual hormones, and serotonin) and xenobiotics (e.g., acetaminophen and morphine are 
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predominantly cleared in this way).  The biological importance of glucuronidation is grossly 
underinvestigated, although it seems reasonable to postulate that it serves primarily to enhance the 
elimination of substrates from the body,65 but in some instances, it may produce more active or more toxic 
compounds.65,66 
 Human UGT genes are classified into four families based on sequence identity: the UGT1 family 
glucuronidates bilirubin and xenobiotic phenols; the UGT2 family glucuronidates steroids and bile acids. 
The function of the UGT3A family is not known, whereas the UGT8A family has only one human gene 
that may be involved in membrane biosynthesis.67 Like the CYPs, each species appears to have its own 
UGTs with various substrates.   
 The human UGT1 subfamily is derived from a single gene with at least 13 individual 
promoters/first exons and a shared set of 2-5 exons.67  The messenger RNA encoding each UGT isoform 
is formed by the fusion of one type of exon 1 to the four exons 2 to 5.   Gene mutations in the common 
exon 2 to 5 regions can lead to changes in activity and/or expression of all isoforms, while gene mutations 
in the unique exon 1 or promoter region may only affect the unique isoform involved.68 Thus, several 
potential transcripts can be generated from the UGT1A locus containing unique 5' ends and identical 3’ 
ends, including 4 enzymes located in the liver (UGT1A1, UGT1A3, UGT1A4 and UGT1A9)  and three 
less-understood enzymes (UGT1A7, UGTA18 and UGT1A10) with no hepatic expression, but mainly 
expressed in gastrointestinal epitheliums.69 Table 760,70-76 provides a description of the UGTs that are 
relevant for neuropsychopharmacology.   
 The UGT2 family has subfamilies that are synthesized from a series of similar genes located in a 
cassette on chromosome 4.  Three olfactory-specific isoforms are included in the UGT2A subfamily.  The 
UGT2B subfamily includes metabolic enzymes that are responsible for the glucuronidation of steroids 
and bile acids.  UGT2B has 12 members, five pseudogenes (inactive genes) and seven genes. Table 7 
describes the two best known, UGT2B7 and UGT2B15. 
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Genetic variations  
 UGT enzymes can be polymorphic but are not understood well enough to develop a clear table 
such as the one for CYPs. UGT1A1 polymorphisms are the best understood. Gilbert's syndrome is a 
genetic variant associated with reduced levels of UGT1A1 that manifests as non-hemolytic unconjugated 
hyperbilirubinemia without hepatic structural damage.77   
 Many polymorphic variations in other UGTs besides UGT1A1 have been identified69,78 but in the 
majority of cases it is not well established whether these variations are functional or not and frequently 
the associated findings with pharmacological changes have not been replicated. Other key genomic 
processes such as copy number variations, epigenetic factors and splicing mechanisms may be important 
for UGT genes, too.79 In summary, no other UGT genetic polymorphism besides UGT1A1, which has 
been recommended for some anti-cancer drugs, is likely to be widely used in the clinical environment in 
the next 5 years and clinicians do not need to be familiar with them.  
Inhibitors 
 VPA can be used as an example of our limited understanding of glucuronidation physiology and 
inhibition. The acyl glucuronide conjugate (valproate-glucuronide or VPAG) appears to be the major 
VPA urinary metabolite and accounts for 30–50% of the VPA dose.80 Five liver UGTs, UGT1A3, 
UGT1A4, UGT1A6, UGT1A9, and UGT2B7 and the primarily intestinal UGTs, UGT1A8 and 
UGT1A10,80,81 may be involved in VPA glucuronidation. According to an in vitro study by Argikar and 
Remmel,80 UGT2B7 has the highest metabolic activity for VPA; with UGT1A6 second, and then the rest 
of the UGTs have similar activity. Argikar and Remmel80 warned that we do not know how to extrapolate 
the clinical relevance of extra-hepatic UGTs, such as UGT1A8 and UGT1A10, due to the lack of data on 
their expression. Besides being metabolized by UGTs, VPA appears to be a clinically relevant inhibitor of 
some of these UGTs. However, it is not easy to definitively establish through a literature review which 
UGTs are inhibited by VPA.   
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 In the neuropsychopharmacology literature there is definitive agreement that VPA inhibits the 
glucuronidation of two drugs, lamotrigine74,80,82 and lorazepam.74,83 They are mainly metabolized by 
UGTs but, because there is no agreement on which UGTs are inhibited by VPA, this inhibition cannot be 
explained.  If one agrees that UGT1A4 is the most important enzyme in lamotrigine metabolism and 
UT2B15 for lorazepam, then VPA is probably a clinically-relevant inhibitor of UGT1A4 and UGT2B15.  
Other articles describe VPA as an inhibitor of UGT2B7,84,85 UGT2B15 and UGT1A9.84 In summary, the 
author is not absolutely sure which UGTs may be inhibited by VPA; the literature provides a complicated 
and sometimes contradictory picture. The literature does not address whether drug inhibition by VPA 
during an in vitro study is a sign of inhibition of a specific UGT or inhibition of multiple UGTs. 
Moreover, it is not clear to the author how an in vitro study using VPA as an inhibitor can be extrapolated 
to an in vivo case in which not only VPA but VPA metabolites are present, probably contributing to UGT 
inhibition, and possibly induction, as Part I of this review article indicates. In summary, we have very 
limited understanding of UGT inhibition (and induction).  
P-gp 
 The relevance of transporters for drug metabolism and DDI has only recently begun to be 
understood, but understanding has rapidly expanded in the last ten years. Although some authors have 
suggested that transporters should be considered as phase III of drug metabolism, this terminology is 
rarely followed.86 Functionally, transporters are classified according to those mediating the uptake of 
drugs into cells (uptake or influx transporters) and those mediating the export of drugs or drug metabolites 
out of cells (efflux transporters).87  
 P-gp is the best-studied drug transporter, but a psychiatrist or neurologist reviewing the literature 
will find it confusing from the start, since the articles use three different names.88 P-gp was initially 
described as a surface glycoprotein modifying the permeability to colchicine in an animal cell model. 
Then it was found to be overexpressed in tumor samples and was associated with resistance to multiple 
drugs; the gene was the called multidrug resistant protein 1 (MDR1) gene. Its high homology with 
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bacterial transporters suggested that P-gp is an efflux transporter. Immunohistochemical studies 
demonstrated P-gp expression in tissues with secretory or excretory functions (liver, kidney, and 
gastrointestinal tract) and at blood-tissue barrier sites, such as the blood-brain barrier (BBB). This pattern 
of expression indicated that P-gp may influence xenobiotic response and toxicity. P-gp was found to be 
part of a very large family of ATP binding transporter genes, some of which are involved in human 
genetic disorders,86 and was renamed ATP-binding cassette sub-family B member 1 (ABCB1). Therefore, 
articles on this subject may use three headings for the same protein or gene:  P-gp, MRD1 or ABCB1.  
 P-gp plays a central role in the absorption, distribution and excretion of a wide variety of drugs. 
Pg-p is expressed in several tissues including intestine, kidney, liver, brain, and placenta.87 It acts as a 
natural defense mechanism against several drugs by limiting their absorption from the gut and penetration 
into the brain, and promoting their elimination in the bile and urine. P-gp is expressed in the apical 
membrane of the entire intestine from duodenum to rectum, with a high expression in enterocytes of the 
small intestine, thereby contributing to a reduced bioavailability of multiple drugs that are substrates of 
this transporter. In hepatocytes P-gp is located in the canalicular membrane and in the kidney at the 
luminal side of proximal tubule epithelial cells mediating the export of xenobiotics into bile and urine, 
respectively.  At the BBB, P-gp is one of the main transporters and is particularly located at the luminal 
endothelial cell, but is present in other cells including neurons and astrocytes.89 The P-gp role at the BBB 
is very poorly understood and includes substrates with a very different structure that binds to more than 
one site of action.90  
 The ABCB1 gene is located on chromosome 7, just as CYP3A4; they appear to have similar 
regulations and site actions and thus they appear to share the same substrates and inhibitors, although they 
may have different affinity for them. It is possible that P-gp may be induced, too, and P-gp 
overexpression may result in the affected drug having limited gastrointestinal absorption or reduced 
penetration to the brain, or enhanced elimination in the bile and urine. At the gut, both CYP3A4 and P-gp 
15 
appear to work in tandem, decreasing the absorption of their common substrate and contributing to what 
was called first-pass metabolism (see CYP section).     
Genetic variations 
 UGT literature is slowly moving to the same type of genetic terminology as the CYP literature. 
However, the articles on ABCB1 genetic variations are much more confusing. They usually focus on 
single nucleotide polymorphisms (SNPs) or haplotypes. A SNP is a DNA sequence variation occurring 
when a single nucleotide (A adenine, T, thymine, C cytosine or G, guanine) varies. A haplotype is a 
combination of alleles at adjacent locations on a chromosome that are inherited together. The lack of use 
of numeric alleles denotes that it is not clear which are associated with functional variations in P-gp 
expression and which are not.91  This is why it is not surprising that attempts to complete meta-analysis of 
the result of associations between ABCB1 genetic variations and AEDs92 or second-generation 
antipsychotics are both negative.93  The existence of many significant findings which are rarely replicated 
suggests to the author that ABCB1 genetic variations will not reach clinical practice in the next five years.  
Drug interactions in general 
 Some articles87 classify P-gp substrates into two groups: 1) the majority of drugs, which are 
substrates of both P-gp and CYP3A4, and 2) those specific to P-gp, which have no CYP metabolism.  The 
latter include a few drugs such as dabigatran (an oral anticoagulant), digoxin and fexofenadine (an 
antihistaminic). It is also believed that not all CYP3A4 substrates are P-gp substrates; midazolam is a 
CYP3A4 substrate but not a P-gp substrate.94     
Quinidine and clarithromycin have been demonstrated to be inhibitors of digoxin and this 
inhibition is thought to be mediated on the basis of potent P-gp inhibition.94,95 However, quinidine is also 
a potent CYP2D6 inhibitor and clarithromycin a potent CYP3A4 inhibitor. Other P-gp inhibitors are 
thought to be verapamil, cyclosporine A, reserpine, yohimbine and tamoxifen.96 Attempts are being made 
to develop highly selective P-gp inhibitors that will not inhibit CYP3A4 or other transporters.96 
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 Similarly, rifampicin and St John’s wort appear to be inducers, as demonstrated by the effects of 
some drugs such as digoxin87,95 and fexofenadine,95 which are P-gp substrates but are not metabolized by 
CYP3A4. The complexity of studying P-gp inducers is suggested by the fact that rifampicin may initially 
be a P-gp inhibitor and increase digoxin absorption, but after some time (one week) it may be a P-gp 
inducer and decrease its absorption.94  
 The best proof that the science on transporters in general and on P-gp in particular may not be 
ready for clinical practice is that a review of drug prescribing information from the USA and Europe 
indicates that frequently information on the same drug does not agree concerning the role of the 
transporter nor even the terminology.87 
Drug interactions in neuropsychopharmacology 
 The P-gp articles on neuropsychopharmacology provide a very confusing picture for clinicians. 
Akamine et al.97 describe almost all antidepressants and antipsychotics as P-gp substrates and report that 
all of them can be inhibitors. On the other hand, Moons et al.93 suggest that not all second-generation 
antipsychotics may be P-gp substrates and O’Brien et al.98 acknowledge that it is not well established 
whether P-gp inhibition by antidepressants is clinically relevant or not. The confusing information 
becomes clearer after reading an AED review, where Zhang et al.99 state that 1) different in vitro models 
of P-gp function provide different results concerning whether AEDs are substrates or not, and 2) there is 
no agreed criteria to define P-gp substrates among AEDs.  Articles tend to describe potent inducers such 
as carbamazepine and phenytoin as P-gp inducers. Valproic acid usually is described not as a P-gp 
substrate but as a P-gp inducer.97 The limited information available suggests that benzodiazepines may 
not be P-gp substrates,100,101 but may be substrates to other efflux transporters located in the BBB.102  
 To further acknowledge our current limitations in understanding DDI mediated by P-gp, it should 
be mentioned that Lin103 proposed that animal studies suggest that DDI at the transport level may have as 
much impact on tissue distribution, particularly in the brain, as on the systemic exposure measured by 
plasma concentrations. If that is true, it will complicate DDI interpretation for clinicians since the first 
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step for interpreting a DDI is to measure plasma concentrations for increases or decreases. One should 
assume a pharmacokinetic component, but if not, one could then consider a pharmacodynamic 
component. If Lin103 is correct that P-gp DDIs have the potential to be pharmacokinetic DDIs, that does 
not influence TDM; these P-gp DDIs may be confused with pharmacodynamic DDIs.  
Induction mechanism and nuclear receptors 
The induction of metabolic enzymes, such as CYPs and UGTs, and transporters, such as P-gp, 
implies that the amount of these proteins increases when they are induced. An increased quantity can be 
reached by increasing synthesis or by decreasing degradation.  The induction of most metabolic enzymes 
and transporters appears to be mainly mediated by increased synthesis. There are two known exceptions: 
CYP2E1 and CYP2D6. CYP2E1 induction appears to be mediated by a completely different mechanism 
at the post-transcriptional level, leading to a stabilization of the protein that delays its destruction. 
CYP2E1 has a short half-life.  CYP2E1 inducers such as ethanol and isoniazid increase CYP2E1 half-life 
by decreasing its degradation.  CYP2D6 has always been considered a CYP isoform that cannot be 
induced; therefore, it is surprising that CYP2D6 activity increases during pregnancy.  In a recent study 
using CYP2D6-humanized mice, Koh et al.24 have proposed that during pregnancy there is a decrease of a 
CYP2D6 repressor.    
Increased synthesis is frequently mediated by a group of receptors that activate genes in the 
nucleus of the cell and are usually called nuclear receptors. As nuclear receptors have the ability to 
directly bind to DNA and regulate the expression of adjacent genes, they are considered transcription 
factors. 
Nuclear receptors consist of 3 major protein domains: 1) a highly conserved DNA-binding domain 
which links the receptor to specific promoter regions of their target genes, 2) a less conserved ligand-bind 
domain, and 3) an area that recognizes other transcription factors and coactivators.104 There is major 
cross-talk between different nuclear receptors and other transcription factors.105 As a matter of fact, one of 
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the receptors described in this section, the aryl hydrocarbon receptor (AhR), is not a nuclear receptor but 
it is part of another superfamily of transcription factors. 
The most important nuclear receptors involved in induction include the pregnane X receptor 
(PXR) and the constitutive androstane receptor (CAR). It is believed that the glucocorticoid receptor 
(GR)106 and the estrogen receptors (ERs)107 may be involved in some induction phenomena.  The estrogen 
receptors may be particularly important in the induction of some enzymes during pregnancy.107 
Some nuclear receptor families include the receptors of steroid (including GR and ER) and thyroid 
hormones that are located in the cytosol but are moved to the nucleus after binding to the substrate. There 
are other receptors that were initially called orphan receptors since their function was not known.108 PXR 
and CAR are included in this category of orphan nuclear receptors; their respective official classifications 
are NR1I2 and NR1I3.109,110  
 One of the problems for clinicians trying to become familiar with this research area is its 
complexity. The role of nuclear receptors goes beyond the effects of xenobiotics such as drugs, pesticides, 
environmental pollutants, carcinogens, or some complex nutrients (e.g., flavonoids), or toxicology and 
pharmacology. Nuclear receptors call into play basic physiology since endogenous compounds including 
biliary compounds, hormones and vitamins bind to these nuclear receptors.  As a matter of fact, these 
receptors regulate one of the most complex biosynthesis processes, the transformation of cholesterol into 
multiple complex biological agents with a complex molecular structure derivate from cholesterol 
including bile acids, corticoids, sexual hormones and vitamin D. To further complicate the literature, there 
are some important differences between human and rodent nuclear receptors, making the literature rather 
complex. As the literature in these nuclear receptors is in its early phases of development and is 
extraordinarily complex, it frequently provides contradictory information. In summary, this section 
provides some hints about how AED inducers may influence CYPs, but no attempt is made to summarize 
the mechanisms of UGT or P-gp induction. Although they are probably driven by the same nuclear 
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receptors, the published information on UGT or P-gp is so contradictory111,112,104 that it is not possible to 
provide a coherent summary for clinicians.   
AhR 
 AhR is reviewed first in this section since it is not really a nuclear receptor. In the absence of a 
ligand, AhR is located in the cytosol but after binding it gets into the cell nucleus and becomes a 
transcription factor. AhRs are widely distributed in many tissues and are probably important for 
embryological development. Several inducers, including some drugs such as omeprazole, cruciferous 
vegetables and polycyclic aromatic hydrocarbons (PAHs) present in smoke, roasted coffee and 
charbroiled meat, bind to AhR, which is important for the induction of the CYP1 family, particularly 
CYP1A2 and some UGTs.   
PXR 
 PXRs are mainly located in the liver and small intestine. Carbamazepine, phenytoin, 
phenobarbital, rifampin and St. John’s wort activate PXRs. PXRs are important for the induction of CYP2 
and CYP3 families and some UGTs. In an in vitro study, Sinz et al.113 explored compounds that activate 
PXRs and classified them according to their potency as CYP3A4 inducers in three groups (rifampicin was 
in the first group of more active compounds; phenytoin and phenobarbital in the second group and 
carbamazepine in the third group).   
 CAR 
CAR is only present in mammals and is mainly located in the liver and kidney. Phenytoin and 
phenobarbital are believed to activate CAR but the process is rather complex and not well understood. 
CAR is an important inducer of CYP2 and CYP3 families and UGT1A1. According to Pascussi et al.,105 
CAR exhibits some pronounced selectivity for CYP2B6 when compared with CYP3A4, but PXR 
regulates both without selectivity.   
ER 
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 According to in vitro studies 1) the high levels of estrogens (multiplied by 100) during pregnancy 
activate both ER and CAR, which has synergistic effects increasing CYP2B6 expression,107 and 2) ER 
may be partly responsible for the UGT1A4 induction seen with high estrogen levels, which may explain 
lamotrigine induction during pregnancy.114   
GR 
 CYP3A4 induction by corticoids such as dexamethasone, prednisolone and methylprednisolone is 
partly mediated by GR, although PXR may also be important.115    
Genetic variations 
There are published attempts to initially explore how genetic variations at AhR, PXR and/or CAR 
can explain differences between individuals in response to inductions.109 The difficulty with interpreting 
these studies is that all review articles in the area insist that nuclear receptors and AhR appear to work in a 
coordinated way with great overlap among these transcription factors and with broad actions at CYPs, 
UGTs, and transporters. Therefore, to study how their genetic variations influence the induction of a drug 
that, for example, is mainly metabolized by CYP1A2, one may need to study all the genetic variations at 
the same time (CYP1A2, AhR, PXR and CAR).   
Complex pharmacokinetic polypharmacy may require modifying correction factors  
 This article provides correction factors in Table 3 with the idea of helping to correct for inductive 
effects in neuropsychopharmacology, which then allows modifying drug dosages to approximate for the 
effect of inducers in a specific patient. The literature, however, warns that extrapolation to an average 
subject is problematic since there is high variability in the population of the effects of inducers.116 
Unfortunately, it is accurate to describe correction factors as gross approximations, but it is better to have 
them that not to have them. 
 This fifth section reviews four situations that may modify the inductive effects: non-oral route, PM 
individuals, presence of inhibitors and presence of other inducers.   
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Non-oral routes, particularly the IV route, are much less influenced by induction than the oral 
route.117  Subjects who do not have an active isoenzyme, such as PMs for CYP2D6 or CYP2C19, cannot 
be induced in that missing CYP but they can be induced in other CYPs. Risperidone is mainly 
metabolized by CYP2D6, but its metabolism is impaired in CYP2D6 PMs, who have approximately half 
the capacity to metabolize risperidone118 and need approximately half the average dose.119  CYP inducers 
cannot induce CYP2D6 but can induce CYP3A4, which is an auxiliary metabolic enzyme of risperidone 
metabolism. As a matter of fact, in the average risperidone subject taking potent CYP3A4 inducers, 
CYP3A4 probably becomes the most important metabolic enzyme for risperidone metabolism; this 
subject needs twice the risperidone dose.119  This approximated correction factor indicates that taking a 
potent CYP3A4 inducer (correction factor 2) and being a CYP2D6 PM (correction factor 0.5) cancel each 
other out, so these subjects have approximately a normal clearance. In the real world, CYP2D6 PMs 
taking potent CYP3A4 inducers have a slightly lower risperidone metabolism than normal.119   
It is difficult to predict the outcomes in situations of combinations of inducers and inhibitors. In 
the case of risperidone, CYP3A4 inducers have more powerful effects that a potent risperidone inhibitor 
such as fluoxetine which inhibits both risperidone metabolic enzymes.119  In this situation of combining 
inhibitors and inducers, it is better to use TDM to establish the outcome. Table 1’s level of induction 
measured by “+” can help clinicians. The effects of potent inducers on CYP3A4 and CYP2B6 is massive 
(4+s in Table 1) and much more important than inhibitor effects.  CYP1A2 induction is probably only 
moderate (2+s in Table 5) and, according to our experience with clozapine potent inducers, tends to have 
less potency than potent inhibitors such as fluvoxamine.120 On the other hand, CYP2C9 and CYP2C19 
induction is minimal (1+ in Table 5) and clearly lower than the effect of potent inhibitors. Phenytoin is 
metabolized by CYP2C9 and CYP2C19 and is an inducer of its own metabolism but these inductive 
effects are probably not very clinically relevant. Phenytoin in high concentrations is a potent inhibitor of 
CYP2C9 and CYP2C19, which is quite clinically relevant during phenytoin intoxication.  In the case of 
drugs metabolized by UGTs, such as lamotrigine, potent AED inducers require duplicating the dose, 
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whereas valproate, a potent inhibitor, requires cutting the dose in half. The combination of potent inducers 
such as phenytoin and valproate require using normal lamotrigine doses. In this situation it may be wiser 
to use lamotrigine TDM since valproate inhibitory effects may be stronger.74  
 The literature provides very little recommendations on how to categorize what happens with 
combinations of inducers.  The author has experience with two types of situations using combinations of 
1) potent AED inducers with other inducers of CYP1A2, and 2) potent and mild AED inducers of 
CYP3A4 drugs.  When patients are taking drugs metabolized by CYP1A2, smoking appears to influence 
induction by AhR, whereas induction by AEDs is mediated by PXR and/or CAR. Therefore, smoking and 
AED inducers appear to have additive and independent effects.120 
When patients are taking CYP3A4 drugs, the effect of potent inducers such as carbamazepine, 
phenytoin or phenobarbital is much more potent than those of mild CYP3A4 inducers such as clobazam, 
eslicarbazepine, oxcarbazepine, rufinamide or topiramate (Table 4).  In those cases, adding a mild inducer 
when a patient is taking a potent inducer may have no effect. Conversely, switching from a potent inducer 
such as carbamazepine to oxcarbazepine is associated with a decrease in inductive effects (increase in 
CYP3A4 substrate levels) and switching from a mild inducer such as oxcarbazepine to carbamazepine is 
associated with an important increase in inductive effects (decrease in CYP3A4 substrate levels).   There 
are not many comparisons in the literature of CYP3A4 inducers, but Ohno et al.,121 after reviewing the 
literature using a complex mathematical model, provide some comparisons of the effects of various 
CYP3A4 inducers. They described metabolism increases of 7.7 by rifampin (450-600 mg/d); 4.7 by 
phenytoin (300-400 mg/day); 3.0 by carbamazepine (200-600 mg/day); 1.4 by efavirenz, an antiretroviral 
agent (600 mg/day); and 1.2 by St. John’s wort (600-900 mg/day).     
Pharmacodynamic DI may also contribute to modification of inducer effects  
The correction factors (Table 3) help clinicians to interpret the effect of adding potent inducers to 
one drug. The prior section tries to give clinicians a first taste of complexity by explaining that the route, 
the individual with PM status, or the co-prescription of inhibitors or other inducers must also be taken into 
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account when interpreting AED inducer effects.  This section tries to focus on the further complexity of 
real-world prescription by describing, as examples, combinations in pairs of three important AEDs, 
carbamazepine, phenytoin and valproic acid; carbamazepine-valproic acid, carbamazepine-phenytoin and 
phenytoin-valproic acid. The author has seen hundreds of epileptic and/or psychiatric patients taking these 
combinations and has found that usually the neurologists and/or psychiatrists managing these patients 
have no clue about the complexity of these DDIs, probably the most complicated DDIs in 
neuropsychopharmacology, and the most uncertain in their outcome.      
Part I describes 1) phenytoin as a powerful inducer of multiple enzymes, which in high plasma 
concentrations can saturate CYP2C9 and CYP2C9, and 2) many of the drugs called mild inducers in this 
article, including VPA, as drugs that can be clinically relevant inhibitors, too.  Thus, a first level of 
complexity is that drugs frequently can be both inducers and inhibitors. Table 8 tries to provide a taste of 
how difficult it can be to interpret these DDIs, since they may combine both complex pharmacodynamic 
and pharmacokinetic components. To master these three AED DDIs, one must master other levels of 
complexity by knowing that protein binding is very important for phenytoin and VPA, and possibly 
relevant at times for carbamazepine.  Another level of complexity is that pharmacodynamic mechanisms 
are also important in interpreting DDIs. Since this review article focuses on induction, it cannot review 
protein binding or pharmacodynamics in detail, but Table 8 provides a comprehensive description of 
complex pharmacological mechanisms of three DDIs. Other prior publications provide more 
comprehensive information, including pharmacodynamic mechanisms and protein binding.74,122,123 In 
summary, the author proposes that psychiatrists and neurologists should not use these three combinations 
unless they thoroughly understand the pharmacological mechanisms behind DDIs and use TDM.     
EXPERIENCE WITH UNUSUAL PATIENTS VERY SENSITIVE TO INDUCERS 
 During the last 15 years as a clinician and consultant for difficult patients in 
neuropsychopharmacology, the author has found a small number of patients with extremely unusual 
pharmacokinetic profiles who appear to be extremely sensitive to inductive effects and need massive 
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doses of some drugs to get therapeutic serum concentrations. After many years of consideration, the 
author thinks that the best way to understand them would be to say that they are candidates for unusual 
genetic profiles at the nuclear receptor levels, which makes them extremely sensitive to inductive effects 
across different metabolic pathways.   
Table 9124-128 lists six patients the author identified as possibly having an excessive response to 
inducers and thus followed. The prevalence of these unusual individuals is unknown, but the author 
estimates they make up between 1/1000 and <1/100 of patients with severe mental illness. Two of the six 
patients needed very high doses of CYP3A4 substrates in the presence of AED potent inducers (Cases 1 
and 3). One patient appeared to be very sensitive to UGT induction; he needed extremely high doses of 
lamotrigine and lorazepam (Case 5). Four of the six patients appeared to have major inductive effects 
secondary to valproic acid demonstrated by TDM effects on valproic acid (Cases 1 and 4), clozapine 
(Case 2) and olanzapine (Case 3). The most perplexing valproic acid case was a case of a patient who 
developed a metastatic renal carcinoma in the context of tuberous sclerosis and required >10g/day of 
divalproex sodium to get therapeutic serum concentrations of valproic acid when co-medicated with 
phenytoin (Case 6). Three UGTs, UGT1A6, UGT1A9, and UGT2B7, are present in high concentration in 
the kidneys.71 As described in Part I, UGT1A6, UGT1A9, and UGT2B7, are probably involved in the 
valproic acid metabolism.74  
CONCLUSION 
This two-part article provides information for clinicians to compensate for the oversight in the 
literature on AED inducers. Part I introduces the subject of potent (Table 1) and mild inducers (Table 4) 
and provides clinical recommendations on correcting for the effect of inducers through dose modifications 
of the induced substrates by using correction factors (Table 3).  
Part II attempts to educate clinicians about the complex nature of interpreting AED DDIs by 
providing basic pharmacological knowledge to help improve their ability to interpret complex DDIs. 
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The basic pharmacology of CYPs, UGTs, P-gp, and nuclear receptors is reviewed. Six CYP 
isoenzymes, CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, are definitively important 
for the metabolism of neuropsychopharmacological drugs. CYP2B6 and CYP3A4 are very sensitive to 
induction.  CYP1A2 is moderately sensitive while CYP2C9 and CYP2C19 are only mildly sensitive. 
Finally, CYP2D6 cannot be induced by medications (Table 5). The genetic variations of CYP2C9, 
CYP2C19 and CYP2D6, are understandable enough for clinical use. PMs are subjects who lack specific 
active CYPs; while they have been identified for CYP2C19 and CYP2D6, their frequencies vary with 
race (Table 6).     
 UGTs are the most important of the conjugation enzymes (traditionally called Phase II metabolic 
enzymes). They are the main metabolic enzymes for a few antipsychotics, a few AEDs, and a few 
benzodiazepines (Table 7). The literature has neglected UGTs; they are less well understood than CYPs.60 
Several important UGTs in neuropsychopharmacology include UGT1A1, UGT1A3, UGT1A4, UGT2B7 
and UGT2B15 (Table 7). There is no definitive information on how inducers influence their activity.  
Similarly, it is not clear how genetic variations or inhibitors (such as valproic acid) influence any of these 
specific UGTs.  
Another major group of pharmacokinetic proteins called transporters can also be induced. They 
usually work in tandem with metabolic enzymes to eliminate xenobiotics from the body.  P-gp is the most 
important transporter and is a major component of the BBB. P-gp science may not be ready for clinical 
practice. US prescribing information and European prescribing information disagree on the relevance of 
transporters and the terminology used to describe them. Moreover, the literature does not agree on which 
neuropsychopharmacological drugs are substrates, inhibitors or inducers for P-gp.   
The new and rapidly expanding literature on nuclear receptors is beginning to provide some 
understanding of how inducers work. The induction of metabolic enzymes such as CYPs and UGTs, and 
transporters such as P-gp, implies that the amount of these proteins increases during induction. This 
increase is almost always explained by increased synthesis mediated by a group of receptors that activate 
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genes in the nucleus of the cell, usually called nuclear receptors. Nuclear receptors are considered 
transcription factors because they can directly bind to DNA and regulate the expression of adjacent genes. 
The most important nuclear receptors involved in induction are PXR and CAR. The hormonal receptors 
GR and ER may also have some role in induction. AhR is not a nuclear receptor but is part of another 
superfamily of transcription factors and mediates smoking’s inductive effects on CYP1A2. The literature 
has initiated exploring how genetic variations at AhR, PXR and/or CAR may explain differences between 
individuals in response to inductions. Nuclear receptors and AhR appear to work in a coordinated way 
with great overlap among these transcription factors and with broad actions at CYPs, UGTs, and 
transporters. Therefore, establishing the induction role of specific genetic variations at individual genes 
will not be easy. 
Table 3 provides correction factors for AED inducers. However, the literature warns that 
extrapolation to an average subject is problematic since there is high variability in the population of the 
effects of inducers. Non-oral routes, particularly the IV route, are much less influenced by induction than 
the oral route.  PMs cannot be induced by the CYP they are missing, but they can be induced in other 
CYPs. It is difficult to predict outcomes when combinations of inducers and inhibitors are present. The 
literature provides very few recommendations on how to explain what happens with combinations of 
inducers.  The author has experience with two types of situations using combinations of 1) potent AED 
inducers with other inducers of CYP1A2, and 2) potent and mild AED inducers of CYP3A4 drugs.   
When patients are taking drugs metabolized by CYP1A2, smoking appears to influence induction by 
AhR, whereas induction by AEDs is mediated by PXR and/or CAR. Therefore, smoking and AED 
inducers appear to have additive and independent effects. When patients are taking CYP3A4 drugs, the 
effect of potent inducers such as carbamazepine, phenytoin or phenobarbital is much more potent than 
those of mild CYP3A4 inducers such as clobazam, eslicarbazepine, oxcarbazepine, rufinamide or 
topiramate (Table 4).  In those cases, adding a mild inducer when a patient is taking a potent inducer may 
have no effect. 
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Table 8 uses as an example the combinations of carbamazepine-valproic acid, carbamazepine-
phenytoin and phenytoin-valproic acid to demonstrate the complexity of understanding some AED DDIs. 
To understand the outcome of these three pairs of combinations, it is not only necessary to take into 
account inductive and inhibitory effects, but pharmacodynamic DDIs and protein binding.  Other prior 
publications provide more comprehensive information, including pharmacodynamic mechanisms and 
protein binding, for understanding DDI in neuropsychopharmacology.74,123,124  
During his last 15 years as a clinician and consultant for difficult patients in 
neuropsychopharmacology, the author has found a small number of patients who have extremely unusual 
pharmacokinetic profiles, probably due to unusual genetic profiles at the nuclear receptor level, which 
makes them extremely sensitive to AED inductive effects across different metabolic pathways. Table 9 
describes six patients including: 1) two needing very high doses of CYP3A4 substrates in the presence of 
AED potent inducers; 2) four with major inductive effects secondary to valproic acid; 3) one very 
sensitive to UGT induction, requiring extremely high doses of lamotrigine and lorazepam; and 4) a patient 
with tuberous sclerosis who needed to take >10g/day of divalproex sodium to get therapeutic serum 
concentrations of valproic acid when taken in combination with phenytoin.  
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Table 1. Characteristics of potent inducers               
                       Metabolic enzymesa    Timeb    
   CYPc    UGTs  Onset  Maximal De-induction Metabolism    Effects in own metabolism    
Carbamazepine CYP2B6, CYP3A4 (++++) Several 1wk130 3 wk130  d3wk129,130    CYP3A4  Auto-induction which takes 3-5 wk 
                          CYP1A2, CYP2A6 (++)           
                          CYP2C (+)                 
Phenytoin CYP2B6,CYP3A4 (++++) Several  1-2 wk130  1-2 wk130 CYP2C9 &  Mild auto-induction 
                        CYP1A2, CYP2A6 (++)        CYP2C19 Competitive inhibition  
                        CYP2C                  
Phenobarbital CYP2B6,CYP3A4 (++++)  UGT1A1 1 wk129 2-3 wk129 2-3 wk129 Kidney  Auto-induction not described 
                        CYP1A2, CYP2A6 (++)        excretion &   
  CYP2C, CYP2E1 (+)        CYP2C9       
++++: massive induction; ++: moderate induction; +: mild induction. wk: weeks.  
aThese potent inducers induce other enzymes including epoxide hydrolase. 
bThese are approximated times provided by review articles.129,130 Readers may need to be aware that few studies have been conducted to verify 
these times.  
cNot all CYPs have the same ability to be induced by potent inducers. More details are provided in Part II, Table 1. It is believed that potent 
inducers have massive effects (++++) on CYP2B6 and CYP3A4. On the other hand, potent inducers have only mild to moderate effects on the 
CYP2C subfamily which includes CYP2C8, CYP2C9 and CYP2C19.131 Although the literature is not specific on this point, the author believes 
that CYP1A2 may be induced intermediately between the potent effects on CYP2B6 and CYP3A4 and mild effects on the CYP2C subfamily 
and described as moderate (++). There is limited information on CYP2A6 suggesting potential for moderate induction (++), but clinicians need 
to be aware that few drugs are metabolized by CYP2A6; this is the main metabolic pathway for nicotine. There is limited information on 
CYP2E1 which may have mild potential for induction, but clinicians need to be aware that few drugs are metabolized by CYP2E1, although it 
is a minor metabolic pathway for alcohol and some antiepileptic drugs. 
dThe loss of induction may take longer for CYP1A2 substrates than for CYP3A substrates (respective induction half-lives were 105 and 70 
hours, or 4.4 days and 2.9 days.132 
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Table 2. Mild inducers: comparison to potent inducers        
     Potent      Mild   
INDUCTION EFFECT SIZE 
   Individual differences  Present in all individualsa   Variable  
   Dose effects    None within therapeutic dosesb  Probably yesc 
   Can be obscured by inhibition Nod      Yes   
     (except phenytoin’s inhibition of CYP2C)     
CHRONOLOGY    
  Onset     Weeks      Weeks 
  Maximum    Weeks      Weeks to monthse 
  De-induction    Weeks      Weeks to monthsf  
aAlthough it has not been systematically studied, it is generally accepted that potent inducers tend to 
maximally induce all patients as long as they are given doses beyond those causing maximal induction.  
bIt is also usually believed that a therapeutic dose for epilepsy should cause maximal induction in most 
patients. Therefore, further increased doses beyond therapeutic doses may not cause more induction. 
Similarly, giving another potent inducer to a person taking usual doses of one potent inducer may not 
make a difference. 
cSee the text for information on dose effects on oxcarbazepine, topiramate and VPA. 
dAEDs which are classified as potent inducers are strong inducers and not clinically relevant inhibitors. 
Therefore, in most circumstances, it is difficult to miss their inductive effects. An exception may be 
phenytoin. See the text on phenytoin. 
eSee the text on vigabatrin in part I. 
fSee the text on oxcarbazepine in part I. 
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Table 3. Correction factors for potent  inducers         
Correction factora  Drug    Reference number      
CARBAMAZEPINE 
>5.0 (7.5)  Quetiapine   122 
5.0   Lurasidone   122 
5.0   Sertraline   133 
2.0-4.0   Clozapine   122 
2.0-4.0   Olanzapine   122 
3.0 (2.5-6.0)  Haloperidol   134,135  
3.0   Paliperidone   136 
2.0   TCAs    123 
2.0   Aripiprazole   122 
2.0   Iloperidone   122 
2.0   Mirtazapine   133 
2.0   Risperidone   122 
2.0   Theophylline   137 
2.0   Topiramate   138,139 
1.5   Felbamate   140 
1.5   Lamotrigine   141,142 
1.4   Citalopram    133 
1.33   Eslicarbazepine   143 
1.33   Clonazepam    144,145 
1.33   Ezogabine (retigabine) 146 
1.25   Paroxetine   147      
1.25   Milnacipran   133        
PHENOBARBITAL 
1.5   Clozapine    120   
1.25   Paroxetine   148      
PHENYTOIN 
5.0   Quetiapine   122 
5.0    Lurasidone   122 
2.0-4.0   Clozapine   122 
2.0-4.0   Olanzapine   122 
2.0   TCAs    123  
2.0   Aripiprazole   122 
2.0   Carbamazepine   149  
2.0   Iloperidone   122 
2.0   Lamotrigine   141,142 
2.0   Mirtazapine   133 
2.0   Risperidone   122 
2.0   Topiramate   138,139 
1.5   Felbamate   140  
1.33-1.5  Oxcarbazepine  150 
1.33-1.5  Clonazepam    151,152   
1.33   Ezogabine (retigabine) 146 
1.33   Eslicarbazepine   143        
1.25   Paroxetine   147      
aBupropion’s correction factor for carbamazepine was 10.0, calculated by the author from the limited 
information available.133  
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Table 4. Mild inducers: their inductive and inhibitory properties       
    Induced enzyme  Inhibited enzyme 
    (or induced druga)  (or inhibited druga)     
Clobazamb   CYP3A4   CYP2C19,c CYP2D6c 
    UGT1A1    UGT1A4,c UGT1A6,c UGT2B4c  
  
Eslicarbazepine  CYP3A4, UGTsd  CYP2C9, CYP2C19 
 
Felbamate   CYP3A4   CYP2C19 
        ß-oxidation 
 
Lamotrigine   UGTsd    (olanzapine)a     
 
Oxcarbazepine (high doses)e CYP3A4   CYP2C19 
    UGT1A4 
 
Rufinamide   CYP3A4   CYP2E1    
    UGTsd 
 
Topiramate (high doses)e CYP3A4   (VPA glucuronidation)a 
    β-oxidation 
    UGT1A4 
 
Vigabatrin   CYP2C9 
 
VPAf    β-oxidation   CYP2C9 
    (aripiprazole)a   UGTsd 
    (clozapine and olanzapine)a Epoxide hydroxylase, N-glucosidation  
VPA: valproic acid. 
aFor drugs in parentheses, the enzyme behind the induction or inhibition is not definitively established. 
bCYP2B6 has not been studied. 
cN-desmethylclobazam is the inhibitor.  
dThe specific UGTs are not known. 
eOxcarbazepine and topiramate may be clinically relevant inducers in high doses (≥ 1200 mg/day for 
oxcarbazepine and ≥400 mg/day for topiramate). It is possible that their inhibitory properties may also be 
more evident in higher doses. 
fVPA induction is probably dose-related. It is probably dependent on the free plasma VPA. VPA follows 
non-linear kinetics, making it difficult to estimate the free plasma VPA using VPA doses. 
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Table 5. CYPs involved in drug metabolism               
                      Inducers   
                Substrates in Neuropsychopharmacology Inhibitors  Level Other (AED/rifampin)   Pregnancy  
CYP1A2 Clozapine, olanzapine    Fluvoxamine  ++  Smokinga            Inhibition 
  Melatonin      Ciprofloxacin   Omeprazole     
  Tacrine     Estrogens   Cruciferous vegetables 
        Infectionb           
CYP2B6 Bupropion     Clopidogrel  ++++ Chinese herbsc                                   Inductiond               
  Ketamine, methadone, ecstasy  Ticlopidine     Antiretroviralse   
            Cotrimazolef 
            Methadoneg       
CYP2C9 Phenytoin, phenobarbital   Fluoxetine  +    St John’s wort    Inductionh 
        Valproic acid           
CYP2C19 Diazepam, clobazam    Fluvoxamine  + St John’s wort           Inhibitioni 
    Citalopram, some TCAsj   Estrogens           
CYP2D6 TCAs, venlafaxine    Paroxetine  No      ↑activityk 
      Risperidone, aripiprazole, iloperidonel Fluoxetine       
  Atomoxetine 
  Activation of codeine-like drugs              
CYP3A4 Carbamazepine    Nefazadone  ++++  St John’s wort        Inductiond       
  Quetiapine, lurasidone   Ketoconazole   Corticoids       
  Midazolam, alprazolam, triazolam  Erythromycin   Cotrimazolef 
  Buspirone     Grapefruit juice  Antiretroviralse      
  Reboxetine, vilazadone               
++++: massive induction; ++: moderate induction; +: mild induction. AED: antiepileptic drug. 
aPolycyclic aromatic hydrocarbons in smoke have inductive effects. These compounds also found on chargrilled food and coffee from roasted 
coffee beans, which can also have inductive effects.22 
bRespiratory infections, other serious infections, such as pyelonephritis or appendicitis or even major inflammations can inhibit CYP1A2 
because the cytokines released inhibit CYP1A2.  
cSodium ferulate was an inducer of bupropion metabolism in a study. It is the sodium salt of ferulic acid, which is widely distributed in herbs 
and Chinese formulas such as Ligusticum, Chuanxiong and Chaihu–Sugan–San.14  Another inducer is baicalin, a flavone glucuronide extracted 
from the medical plant Radix scutellariae, which is present in fruits, vegetables, and beverages derived from plants (tea, red wine), and in a 
wide range of herbal medicines including Huang-Lian-Jie-Du-Tang, hangeshashinto, San-Huang-Xie- Xin-Tang, Da-Chai-Hu-Tang, and Xiao-
Chai-Hu-Tang.15 
dPregnancy definitively induces CYP2B6 and  CYP3A4.25 According to an in vitro study, CYP2B6 and CYP3A4 are induced by both estrogen 
and progesterone. Progesterone also induces CYP3A5.   
eEfavirenz16 and ritonvir17 are definitively CYP2B6 inducers. Several antiretroviral agents can induce CYP3A4.18,19 
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fCotrimazole may be an inducer of CYP2B6 and CYP3A4.21  
gIn vitro studies indicate that methadone may induce its own metabolism and this may be mediated not only by CYP2B6 but also by 
CYP3A4.20 
hIt is believed that CYP2C9 increases during pregnancy because phenytoin clearance increases. It cannot be ruled out that mechanisms other 
than CYP2C9 induction may explain changes in phenytoin clearance during pregnancy. Estradiol increases the activity of CYP2C9 without 
affecting expression by unknown mechanisms.26   
iEstrogens are thought to be competitive inhibitors of CYP2C19, but a recent study suggested that they may inhibit CYP2C19 expression.12  
jCYP2C19 is the main enzyme to demethylate amitriptyline, clomipramine and imipramine. Their metabolites then are further metabolized by 
hydroxylation, mainly by CYP2D6.   
kIt is not well understood why CYP2D6 activity may increase in pregnancy, since it is believed that CYP2D6 cannot be induced. A recent study 
suggested that pregnancy may remove a suppressor of CYP2D6 expression.24 
lAripiprazole, iloperidone and risperidone are mainly metabolized by CYP2D6, but CYP3A4 is also an important pathway, which may be even 
more important under treatment with inducers. 
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Table 6. CYP involved in drug  metabolism: Genetic variations       
           Unusual subjects      
  Knowledge  PM    Slow   UM      
CYP1A2 Limiteda         Very rareb       Very rareb 
          
CYP2B6 Limitedc            In Africansd  Frequente  Unknown                           
                  
CYP2C9 Clinical tests     Frequentf    
 
CYP2C19 Clinical tests    25% East Asiansg    1-5%h 
    <5% other racesg 
 
CYP2D6 Clinical tests    7% Caucasiansi 50% East Asiansj 40% North Africak  
    <5% other races 30% Africansl  >20% Oceaniak 
       10-15% Caucasians 1-5% Caucasiansk  
          1-2% in USm 
  
CYP3A4 Limitedn No   Possibleo  No                   
 
CYP3A5 Limitedp Unclear         
≈: approximately. PM: poor metabolizer. UM: ultrarapid metabolizer. AA: African Americans.  
aSome studies indicate that some alleles may influence induction. CYP1A2*1C has been associated with 
low inducibility and CYP1A2*1F with high inducibility but there is not complete agreement in the 
literature.30,31  
bCYP1A2 review articles31 usually report that there are no clearly identified PMs with missing enzyme or 
UMs with clearly increased activity. Rarely, clozapine literature describes some extreme subjects 
compatible with being CYP1A2 PM (e.g., a patient with one CYP1A2*7 allele41). Some cases with a UM 
profile have been described but no clear genetic variants have been identified.42,43  
cCYP2B6 activity is associated with a large number of CYP2B6 genetic variations including single 
nucleotide polymorphisms and haplotypes.33  
dCYP2B6*18 occurs predominantly in Africans and does not express a functional protein, at least for 
some substrates. Frequencies of individuals with only one deficient allele are described as 5-12% of 
Africans and 4-8% of African-Americans.14 Thus, although PM frequencies are not described in articles, 
PM frequencies should be expected to be <1% in the general population.  
eCYP2B6*6 is probably the most frequent low functioning allele and occur 15% to over 60% in different 
populations.32 
fSeveral frequent CYP2C9 alleles have lower activity: CYP2C9*1 is the normal allele and a subject with 
*1/*1 will have an activity of 1.0.  CYP2C9*2 has lower activity, according to Castellan et al.20; a subject 
with *2/*2 will have an activity of 0.70 while a subject with *1/*2 will have an activity of 0.82. 
CYP2C9*3 has very low activity, according to Castellan et al.40 a subject with *3/*3 will have an activity 
of 0.13 while a subject with *1/*3 will have an activity of 0.56 and *2/*3 will have an activity of 0.39.  
Therefore, for *3/*3 a dose reduction of 65% of phenytoin and 85% of phenobarbital is recommended.     
gFor CYP2C19, the most important inactive alleles are *2 and *3, which are frequent in East Asians.38 
hCYP2C19 *17 is associated with increased activity. Scott et al. (2011)52 described 21% of Europeans and 
18% of Africans as having one CYP2C19*17 allele. With these frequencies, it can be estimated that 
approximately 4% of Europeans and 3% of Africans would have two alleles with increased activity and 
may be considered CYP2C19 UMs (CYP2C19*17/CYP2C19*17).  Other authors argue that 
CYP2C19*17 may be irrelevant for the majority of drugs.53 
iThe most important CYP2D6 inactive alleles are *3, *4, *5 (deletion) and *6.38 
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Different review articles provide different prevalences of CYP2D6 PMs. In a recent review, McGraw and 
Waller45 described 3-10% in Caucasians, 0-19% in African Americans, 6.0% in Hispanics, 0-4.4% in 
Native Americans and 0.3% in East Asians.  
jIn CYP2D6, the slow metabolizers are usually called intermediate metabolizers (IMs), but the 
terminology varies from laboratory to laboratory. Sometimes CYP2D6 tests describe subjects with at least 
one normal allele as intermediate metabolizers while others will consider that an EM.27,38 East Asians 
frequently have *10. Assuming that two normal active alleles have an activity of 1, one active allele and 
*10 have an activity level of 0.54 and two *10 only 0.10.49  
kAccording to Tod et al.,49 typical CYP2D6 UMs with 3 active alleles (1 normal allele in one 
chromosome and duplication in the other) have an activity level of 1.67 (1.15-2.21). A comprehensive 
worldwide study provided these frequencies.54 
lCYP2D6*17 is found in individuals with African ancestry and usually has lower activity, but has normal 
activity for risperidone.37 
mIn a large study in a U.S. psychiatric hospital,37 the prevalence of CYP2D6 UMs was 1.5% (95% 
confidence interval, CI, 1.1, 1.9). In African Americans it was 2.0% (95% CI 1.1, 3.7) for many drugs but 
as CYP2D6*17 may have normal activity for risperidone, the frequency of UMs for risperidone was 
slightly higher at 2.9% (CI 1.7, 4.9). 
nCYP3A4 expression and activity greatly vary interindividually, but it is believed that is due not only to 
genetic factors but to nongenetic factors such as hormone and health status, and the impact of 
environmental stimuli. Most of the described genetic variants have no functional consequences or are too 
rare to contribute significantly to the CYP3A4 variability.34  
oA new allele CYP3A4*22, associated with low activity, has been described in 5-7% of Caucasians.50 It 
may have clinical relevance for CYP3A4 drugs such as quetiapine.51 
pCYP3A5 literature is rather confusing. The traditional story is that there are 3 alleles with no or low 
expression: CYP3A5*3, CYP3A5*6 and CYP3A5*7.  CYP3A5*6 and CYP3A5*7 are only found in 
people with African ancestry. Individuals are usually classified as high and low CYP3A5 expressors. 
Approximate frequencies of high expressors are 70% in Africans and 10% in Caucasians.34   More 
recently, Bains et al.35 reported that it is not definitively established that CYP3A5*6 is associated with 
lower expression; even assuming that the number of high expressors in African populations varies widely, 
it may average 43%. To make the CYP3A5 story more confusing, the relevance of CYP3A5 
polymorphism may vary from drug to drug and is not definitively established.34  
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Table 7. UGTs involved in drug metabolism          
  Hepatic    Substrates       
  expression Probea    Neuropsychopharmacologyb      
UGT1A1 Yes  Bilirubin  Buprenorphine    
       Ezogabine (retigabine)     
 
UGT1A3 Minor  R-lorazepam  VPA     
       Amitriptyline 
       Clozapine       
 
UGT1A4  Yes  Trifluoperazine Many TCAs    
       Olanzapine, clozapine, asenapine 
Loxapine, phenothiazines,c 
       Lamotrigine, VPA      
 
UGT1A6 Yes  Serotonin  VPA        
 
UGT1A8 No     VPA        
 
UGT1A9 Yes  Propofol  Ezogabine (retigabine)    
       VPA        
 
UGT1A10 No  Dopamine  VPA        
 
UGT2B7 Yesi  Morphined  Many opioidse    
       Oxazepam    
       VPA 
       Carbamazepine     
       Haloperidolf       
 
UGT2B15 Yes  S-lorazepam  Lorazepam     
    S-oxazepam          
aProbes are drugs that are used to study the specific enzyme since they will be relatively specific 
substrates, but for UGTs different articles provide different probes. Only one recent article by an expert in 
the area73 was used to develop this column. 
bUpdated from de Leon60 by using de Leon et al.74 
cChlorpromazine and trifluoperazine are phenothiazines that definitively are UGT1A4 substrates.  
dMorphine is metabolized to a 3-glucuronide with no analgesic effect by UGT2B7, UGT1A8, and 
UGT1A3  and to a 6-glucuronide that is more potently analgesic than morphine, mainly by UGT2B7.75 
eMany opioids are glucuronized by UGT2B7 besides morphine, including buprenorphine, codeine, 
naloxone and naltrexone. Buprenorphine and naltrexone can also by glucuronized by UGT1A1.60  
fA recent in vitro study76 indicated that haloperidol is mainly glucuronized by UGT2B7 with minor 
contributions of UGT1A4 and UGT1A9. These UGTs would be responsible for 50-60% of haloperidol 
clearance versus 20-30% from CYP3A4. 
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Table 8. Complex pharmacokinetic and pharmacodynamic AED combinations     
CARBAMAZEPINE and VPA 
Summary for clinicians: Be very careful and use TDM, including free concentrations.  
PHARMACOKINETICS EFFECTS 
Effects of VPA on serum carbamazepine concentrations: ↑ total and free  
 (-) epoxide hydoxylase: ↑ serum epoxide concentration  
 (-) UGT2B7: ↓ serum glucuronidate diol metabolite 
 Displace carbamazepine from binding to plasmatic proteins                                                        
Effects of carbamazepine on serum VPA concentrations: ↓ total and ↑ free 
 Probably inhibition of some metabolic enzymes 
 Displace VPA from binding to plasmatic proteins  
PHARMACODYNAMICS EFFECTS (poorly understood): 
Carbamazepine blocks of voltage-gated sodium channels and VPA have complex anti-convulsant effects.      
Possible additive mood stabilizer effects by acting at the intracellular signaling system. 
Textbooks usually report increased risk for neurological ADRs.       
CARBAMAZEPINE and PHENYTOIN 
Summary for clinicians: Be very careful and use TDM, including free concentrations. 
PHARMACOKINETICS 
Effects of phenytoin on serum carbamazepine concentrations: ↓ total and ↑ free  
  Further enzymatic induction 
    Displace carbamazepine from binding to plasmatic proteins                                                        
Effects of carbamazepine on serum phenytoin concentrations: unclear 
  Possible further enzymatic induction 
    Displace phenytoin from binding to plasmatic proteins   
  Possible CYP2C19 inhibition 
PHARMACODYNAMICS(poorly understood): 
Probably additive anti-convulsant and ADRs: both are blockers of voltage-gated sodium channels  
PHENYTOIN and VPA 
Summary for clinicians: Be very careful and use TDM, including free concentrations. 
PHARMACOKINETICS 
Effects of phenytoin on serum VPA concentrations: ↓ total and ↑free  
 Enzymatic induction 
   Displace VPA from binding to plasmatic proteins    
Effects of VPA on serum phenytoin concentrations: ↑ total and free  
Powerful CYP2C9 inhibition 
   Displace phenytoin from binding to plasmatic proteins   
PHARMACODYNAMICS (poorly understood): 
Phenytoin blocks of voltage-gated sodium channels and VPA have complex anti-convulsant effects  
(-): inhibition. ADRs: adverse drug reactions. AED: antiepileptic drugs. TDM: therapeutic drug 
monitoring. VPA: valproic acid. 
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Table 9. List of patients with extreme sensitivity to inductive effects.      
Case 1: Caucasian ♂ inpatient with schizophrenia and late-onset epilepsya 
   A) Extreme sensitivity to CYP3A4 induction  
-Carbamazepine: 1500-2000 mg/dayb was needed in the past to reach therapeutic serum             
concentrations. 
-Quetiapine: On phenytoin and VPA, the quetiapine C/D ratio was 10 times lower than expected. 
                                 On VPA, the quetiapine C/D ratio was 2-6 times lower than expected. 
-Diazepam:c On phenytoin, serum concentrations were undetected despite taking 30 mg/day. 
                                 On VPA, diazepam clearance after 30 mg IM was ≥3 times higher than expected. 
   B) Possible VPA auto-induction when taking concentrate, but not present on divalproex sodium 
                                 On concentrate, 5250 mg/dayd was needed to reach therapeutic concentrations.  
           On divalproex sodium, 2000 mg/daye was enough for therapeutic concentrations.  
  C) Metabolism of clozapine and olanzapine (CYP1A2 drugs) was normal for a male smoker.f   
Case 2: African-American ♂ inpatient with schizoaffective disorderg 
A)Extreme clozapine induction by VPA (divalproex sodium) 
       -Smoking (20 cigarettes/day): ≥ 650 mg/day was needed for reaching serum concentrations >350ng/mlh  
        During smoking induction, the patient demonstrated a high metabolic capacity for clozapine. 
      - Smoking and VPA: ~1200 mg/day was needed for reaching serum concentrations >350ng/mli 
        Addition of VPA induction led to the highest clozapine metabolic capacity the author has seen.  
Case 3: Caucasian ♂ inpatient with schizoaffective disorderj 
  A)Extreme sensitivity to CYP3A4 induction  
-Carbamazepine: Up to 2800 mg/dayb was needed to reach therapeutic serum concentrations;  
        this is partly explained by deposits in fat tissue and high volume of distribution.k    
-Risperidone: On carbamazepine, approximately 4 times higher than normal metabolic capacity. 
                                   On divalproex sodium, risperidone metabolism was normal. 
-Paliperidone: On carbamazepine, high capacity to metabolize paliperidone. 
  B) Extreme olanzapine induction by VPA (divalproex sodium) and omeprazole 
            -Olanzapine: On divalproex sodium and omeprazole, 1.5 - 2 times higher than normal metabolism. 
Case 4: Caucasian ♂ inpatient with bipolar disorderl 
  A)Possible VPA auto-induction when taking divalproex sodium 
           - Discharged on 4000 mg/daym         ______ 
Case 5: Caucasian ♂ inpatient with frontal and temporal lobe epilepsy and psychosisn 
A) Extreme sensitivity to UGT induction during phenytoin and phenobarbital treatment 
-Lamotrigine: 2.6 times higher than the recommended dosage was needed.o  
            -Lorazepam: Doses > 20 mg/day were tolerated with no sedation.      
Case 6: Caucasian ♂ inpatient with tuberous sclerosis and kidney tumorsp 
  A) Increased VPA metabolic capacity when taking phenytoin and VPA 
  -Divalproex sodium: Dose increased >10,000 mg/day to reach therapeutic serum concentrations.q 
            -Phenytoin: No changes in phenytoin metabolism and no need for changes in dosage.      
aFollowed for 5 years (ages 30 to 35). 
bUsual carbamazepine doses to reach therapeutic concentrations: 800-1200 mg/d. Maximum 
recommended dose is 1600 mg/day.124 
cDiazepam is metabolized primarily by CYP2C19; CYP3A4 is an auxiliary enzyme. In this patient 
CYP3A4 was probably the primary metabolic enzyme for diazepam.  
dThe data was published without a pharmacological explanation.125 VPA C/D ratio was 0.013-0.017. 
eThe data was published without a pharmacological explanation.125 VPA C/D ratio was 0.036-0.048. 
fClozapine C/D ratios have been published.126 
gFollowed for > 1 year (age 38) 
hClozapine C/D ratios ranging from 0.54-0.57 were published.127  
iClozapine C/D ratios ranging from 0.27-0.37 were published.127  
55 
jFollowed for > 1 year (age 28). 
kAt the time of highest carbamazepine dose, BMI was 40 with weight of 191 kg. The high dose is partly 
explained by obesity.128 
lFollowed for 3 months (age 68). 
mVPA C/D ratio was 0.024-0.033 in the first month and decreased to 0.017-0.018 in the second month. 
nFollowed for 1 year (age 24). 
oPatient needed 1600 mg/day to get therapeutic serum lamotrigine concentrations. The maximum 
recommended dose is 600 mg/day.   
pFollowed for 4 years (ages 44 to 48 until he died). He initially had angiomyolipomas in both kidneys. In 
the second year, a growing right kidney mass led to possible diagnosis of renal carcinoma and 
nephrectomy pathology that suggested angiomyolipoma. In the third year, brain metastasis became 
evident.   
qIn the beginning when the patient had bilateral kidney tumors, he needed around 5000 mg/day of 
divalproex sodium to get therapeutic concentrations with VPA C/D ratios of 0.010-0.018. After 
nephrectomy and obvious metastatic renal cancer was present, he needed 10,500 mg/day of divalproex 
sodium to get therapeutic concentrations with VPA C/D ratios of 0.005-0.009. 
 
 
 
